BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220913
DTEND;VALUE=DATE:20220917
DTSTAMP:20260516T033510
CREATED:20220516T094442Z
LAST-MODIFIED:20220516T094442Z
UID:34110-1663027200-1663372799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Revolutionizing Genetic Therapy Development & Delivery to the Eye \nDiscovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches \nThe ophthalmology field is bursting with novel genetic approaches for targeting many disorders\, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic\, as well as more innovative outpatient methods such as suprachoroidal delivery\, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders. \nReturning for its 3rd year\, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges\, with focus on discussing and sharing solutions with the key leaders in the industry. \nThis year we have expanded into two streams of learning\, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development. \nGene therapy for ophthalmic disorders has only seen one FDA approved therapy\, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market. \nLeave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments\, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-ophthalmic-disorders/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR